Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02273193 · ClinicalTrials.gov registry record

Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes

A clinical trial of Gestational Diabetes Mellitus, sponsored by Mike O'Callaghan Military Hospital.

Completed
Registry status
643
Enrollment target
1
Study location

NCT02273193: Completed study of Gestational Diabetes Mellitus, sponsored by Mike O'Callaghan Military Hospital.

NCT02273193 is a study of Gestational Diabetes Mellitus that has completed, run by Mike O'Callaghan Military Hospital. The registered enrollment target is 643 participants, above the 379-participant average among 16 other Gestational Diabetes Mellitus trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02273193, a study of Gestational Diabetes Mellitus, has completed, sponsored by Mike O'Callaghan Military Hospital.

COMPLETED
Registry status
643 participants
Enrollment target
1
Study location

Study Summary

A prospective cohort research study is being conducted in the Mike O'Callaghan Federal Medical Center (MOFMC), Department of Family Medicine, Obstetrics Clinic to determine if early screening with hemoglobin A1C, a blood test for blood glucose, can be used to identify women with hyperglycemia or Gestational Diabetes Mellitus (GDM) in the first semester of pregnancy in place of a fasting blood glucose blood test. This study will also determine how hemoglobin A1C compares with the oral glucose tolerance test (GTT) done as a standard of care with the standard of care second trimester prenatal care testing. Subjects recruited and consented during the Obstetrics Orientation Class will have two (2) additional blood tests drawn with their standard of care prenatal tests in the first trimester (\<13 weeks) of pregnancy and at the second trimester (24-28 weeks) of pregnancy. Subjects identified as having GDM by blood HbA1C, fasting glucose or the 2 hr OGTT will be treated for GDM with standard of care by their primary care provider. The correlation of blood HbA1C with the fasting glucose in the first trimester of pregnancy and with the 2 hr OGTT will be determined for early detection and diagnosis of GDM. This study will contribute to understanding the role of HbA1C in pregnancy and the development of GDM.

Study Locations (1)

Nevada

  • Mike O'Callaghan Federal Medical Center - Nellis Air Force Base

Trial Details

FieldValue
Enrollment Target 643 participants
Start Date 2014-10-14
Est. Completion 2017-07-01
Mike O'Callaghan Military Hospital

26 total trials

What the finished NCT02273193 record still lists

NCT02273193 is an observational study that tracks outcomes without assigning an intervention. The registered 643 participants enrollment target is mid-sized for trials with a published cap, above the 379-participant average among 16 other Gestational Diabetes Mellitus trials with a reported enrollment target (70% higher).

The record links to 1 condition, with Gestational Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.

NCT02273193 reports a single indexed study location in Nevada.

Frequently Asked Questions

What is clinical trial NCT02273193 about?

NCT02273193 is a clinical study titled "Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes". A prospective cohort research study is being conducted in the Mike O'Callaghan Federal Medical Center (MOFMC), Department of Family Medicine, Obstetrics Clinic to determine if early screening with hemoglobin A1C, a blood test for blood glucose, can be used to identify women with hyperglycemia or Ges...

What is the current status of trial NCT02273193?

This trial is currently completed. The enrollment target is 643 participants. The study started on 2014-10-14. Estimated completion is 2017-07-01.

What conditions does trial NCT02273193 study?

This clinical trial studies the following conditions: Gestational Diabetes Mellitus.

Who is sponsoring clinical trial NCT02273193?

This trial is sponsored by Mike O'Callaghan Military Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02273193 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gestational Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02273193's enrollment target sits among peer trials

643 3rd of 16 higher than 14 of 16 other Gestational Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gestational Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05146297 · 644 participants · NA

    Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials

  • NCT06994442 · 644 participants · Phase 3

    Optimizing Pain Treatment in Children On Mechanical Ventilation

  • NCT05204888 · 642 participants · NA

    myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

  • NCT07012395 · 645 participants · Phase 2

    A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02273193, the US trial registry maintained by the National Library of Medicine. NCT02273193 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.